Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

The disclosure provides at least one entity chosen from compounds of Formula (I)

##STR00001##

pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

The disclosure provides at least one entity chosen from compounds of Formula (I)

##STR00001##

pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

Provided are a compound of formula (I-a), an isomer thereof or a pharmaceutically acceptable salt thereof as a Hemagglutinin inhibitor, and a preparation method thereof. The compound is useful for preparing a medicament for treating a disease related to Hemagglutinin.

##STR00001##

Provided are a compound of formula (I-a), an isomer thereof or a pharmaceutically acceptable salt thereof as a Hemagglutinin inhibitor, and a preparation method thereof. The compound is useful for preparing a medicament for treating a disease related to Hemagglutinin.

##STR00001##

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M.sub.1 (mAChR M.sub.1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.